Omega-3-acid ethyl esters


Omega-3-acid ethyl esters
Accession Number
DB09539  (DB09540)
Small Molecule
Approved, Investigational

Omega-3 acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester and docosahexaenoic acid-ethyl ester that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia.

  • omega-3 Fatty acid ethyl esters
External IDs
K-85 / K85 / TAK-085
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
LovazaCapsule, liquid filled1 g/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2008-10-212016-12-22Us
LovazaCapsule, liquid filled900 mg/1OralAtlantic Biologicals Corps.2008-10-21Not applicableUs
LovazaCapsule, liquid filled1 g/1OralCardinal Health2008-10-212018-03-20Us
LovazaCapsule, liquid filled900 mg/1OralAtlantic Biologicals Corps.2016-05-19Not applicableUs
LovazaCapsule, liquid filled1 g/1OralRebel Distributors2008-10-21Not applicableUs
LovazaCapsule, liquid filled1 g/1OralPhysicians Total Care, Inc.2008-12-11Not applicableUs00173 0783 62 nlmimage10 4a192579
LovazaCapsule, liquid filled900 mg/1OralGlaxosmithkline Inc2016-05-19Not applicableUs
LovazaCapsule, liquid filled900 mg/1OralGlaxosmithkline Inc2008-10-21Not applicableUs
OmtrygCapsule900 mg/1OralTrygg Pharma, Inc.2015-09-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Omega-3 Well PackKitOralTmig, Inc.2015-09-01Not applicableUs
Omega-3-acid ethyl estersCapsule, liquid filled1 g/1OralAv Kare, Inc.2015-05-07Not applicableUs
Omega-3-Acid Ethyl EstersCapsule, liquid filled900 mg/1Oralbryant ranch prepack2014-06-30Not applicableUs
Omega-3-acid ethyl estersCapsule, liquid filled1 g/1OralAmerincan Health Packaging2015-06-05Not applicableUs
Omega-3-Acid Ethyl EstersCapsule, liquid filled1 g/1OralAtlantic Biologicals Corps.2015-11-30Not applicableUs
Omega-3-acid Ethyl EstersCapsule, liquid filled900 mg/1OralAvera Mc Kennan Hospital2015-04-28Not applicableUs
Omega-3-acid ethyl estersCapsule, liquid filled1 g/1OralApotex Corporation2014-09-30Not applicableUs
Omega-3-Acid Ethyl EstersCapsule, liquid filled1 g/1OralAmneal Pharmaceuticals2015-11-30Not applicableUs
Omega-3-acid ethyl estersCapsule900 mg/1OralPar Pharmaceutical2017-09-19Not applicableUs
Omega-3-acid Ethyl EstersCapsule1 g/gOralInternational Brand Management, Llc2016-04-09Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Concept DHAOmega-3-acid ethyl esters (200 mg/1) + Biotin (300 ug/1) + Cupric sulfate (2 mg/1) + Cyanocobalamin (12.5 ug/1) + Folic Acid (1 mg/1) + Iron (53.5 mg/1) + Iron (38 mg/1) + Magnesium sulfate (5 mg/1) + Niacin (1.8 mg/1) + Calcium pantothenate (5 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (3 mg/1) + Thiamine mononitrate (2 mg/1) + Vitamin C (25 mg/1) + Zinc sulfate (10 mg/1)Capsule, liquid filledOralUs Pharmaceutical Corporation2009-06-24Not applicableUs
DivistaOmega-3-acid ethyl esters (300 mg/1) + Biotin (2 mg/1) + Chromium picolinate (1000 ug/1) + Cyanocobalamin (15 ug/1) + Folic Acid (1 mg/1) + Pyridoxine (25 mg/1)CapsuleOralUs Pharmaceutical Corporation2010-07-10Not applicableUs
Tandem DHAOmega-3-acid ethyl esters (310.1 mg/1) + Folic Acid (1 mg/1) + Iron (15 mg/1) + Iron (15 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Vitamin C (20 mg/1)CapsuleOralUs Pharmaceutical Corporation2007-01-17Not applicableUs
CAS number
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
Not Available
Not Available
Not Available



Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG).

Structured Indications

In healthy volunteers and in subjects with hypertriglyceridemia, EPA and DHA were absorbed when administered as ethyl esters orally. Omega-3-acids administered as ethyl esters (Omega-3-Acid Ethyl Esters capsules) induced significant, dose-dependent increases in serum phospholipid EPA content, though increases in DHA content were less marked and not dose-dependent when administered as ethyl esters.

Mechanism of action

The mechanism of action of Omega-3-Acid Ethyl Esters is not completely understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal β-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. Omega-3-Acid Ethyl Esters may reduce the synthesis of triglycerides in the liver because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids.


When Omega-3-Acid Ethyl Esters was administered under fasted condition, on average the peak (Cmax) and total (AUC0- 72h) exposure were lower by up to 20 to 80-fold, respectively, for total plasma EPA, and lower by up to 2 to 4-fold, respectively, for total plasma DHA, in comparison to those observed under fed condition (high-fat high-calorie meal). Therefore, OMTRYG should be taken with food. In healthy volunteers and in patients with hypertriglyceridemia, EPA and DHA were absorbed when administered as ethyl esters orally. Omega-3-acids administered as ethyl esters induced significant, dose-dependent increases in serum phospholipid EPA content, though increases in DHA content were less marked and not dose-dependent when administered as ethyl esters.

Volume of distribution

82 L

Protein binding
Not Available

Omega-3 fatty acids are metabolized into usable eicosanoids, including leukotrienes and prostaglandins, then esterfied and hydrolyzed from tissue and transformed into polyunsaturated fatty acids.

Route of elimination

Includes oxidative catabolism to carbon dioxide and water

Half life

9 hours


57 mL/h,

Not Available
Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
Not Available
Food Interactions
Not Available


General References
  1. Braeckman RA, Stirtan WG, Soni PN: Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects. Clin Pharmacol Drug Dev. 2014 Mar;3(2):101-108. Epub 2013 Oct 22. [PubMed:26097787]
  2. FDA label [Link]
External Links
PubChem Substance

Clinical Trials

Clinical Trials
0Active Not RecruitingSupportive CareCancer, Breast1
0CompletedTreatmentHealthy Volunteers1
0Not Yet RecruitingTreatmentCancer, Breast1
1CompletedTreatmentSevere Hypertriglyceridemia1
1TerminatedTreatmentFatty Liver / Non-Alcoholic Fatty Liver Disease (NAFLD)1
1, 2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2CompletedTreatmentHypertriglyceridemias1
1, 2CompletedTreatmentIncreased Drug Resistance1
1, 2Not Yet RecruitingTreatmentColorectal Cancers1
1, 2Not Yet RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
1, 2Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Not Yet RecruitingTreatmentMelanoma1
1, 2Not Yet RecruitingTreatmentNeuroendocrine Carcinoma of the Skin1
1, 2Not Yet RecruitingTreatmentNon Hodgkin Lymphoma (NHL)1
1, 2Not Yet RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
1, 2Not Yet RecruitingTreatmentTransitional Cell Carcinoma1
1, 2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)2
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentMyocardial Infarction (MI)1
1, 2WithdrawnTreatmentLiver Diseases / Short Bowel Syndrome (SBS)1
2Active Not RecruitingTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
2CompletedNot AvailableHeart Diseases / Human Immunodeficiency Virus (HIV) Infections1
2CompletedPreventionCancer, Breast2
2CompletedPreventionColorectal Adenomatous Polyps1
2CompletedTreatmentCardiovascular Disease (CVD) / Haemorrhage1
2CompletedTreatmentExocrine Pancreatic Insufficiency / Type 2 Diabetes Mellitus1
2CompletedTreatmentMuscle Damage / Muscle Inflammation1
2CompletedTreatmentNon Familial Chylocmicronemia Syndrome (Non-FCS)1
2CompletedTreatmentSevere Hypertriglyceridemia1
2TerminatedTreatmentHepatic Steatosis / Nonalcoholic Steatohepatitis (NASH)1
2Unknown StatusSupportive CareCombat Disorders / Depression / Moods Disorders / Stress Disorders1
2, 3CompletedTreatmentHypertriglyceridemias1
3CompletedTreatmentDeath, Sudden,Cardiac / Myocardial Infarction (MI)1
3CompletedTreatmentInsulin Resistance1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3TerminatedPreventionCardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Endocrine System Diseases / Glucose Metabolism Disorders / Heart Diseases / High Blood Pressure (Hypertension) / Metabolic Diseases / Vascular Diseases1
3TerminatedTreatmentHeart Failure, Unspecified1
4Active Not RecruitingPreventionDiabetes Mellitus (DM)1
4CompletedNot AvailableMixed hypercholesterolemia1
4CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Dyslipidemias / Human Immunodeficiency Virus (HIV) Infections / Hypertriglyceridemias1
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentBipolar Disorder (BD) / High Blood Cholesterol Level / High Triglycerides / Schizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentCardiovascular Disease (CVD) / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentDiabetic Neuropathies / Hypertriglyceridemias1
4CompletedTreatmentHigh Triglyceride Level / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHypertriglyceridemias / Metabolic Syndromes1
4CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
4Unknown StatusTreatmentHypercholesterolemia, Familial1
4Unknown StatusTreatmentHypertriglyceridemias1
4Unknown StatusTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
4Unknown StatusTreatmentNonvalvular Atrial Fibrillation1
4Unknown StatusTreatmentMixed hypercholesterolemia1
Not AvailableActive Not RecruitingNot AvailableHyperlipidemias1
Not AvailableActive Not RecruitingBasic ScienceInsulin Resistance / Metabolic Syndromes1
Not AvailableCompletedNot AvailableHyperlipidemias1
Not AvailableCompletedBasic ScienceCardiovascular Disease (CVD)1
Not AvailableCompletedBasic ScienceHypertriglyceridemias1
Not AvailableCompletedBasic ScienceInflammatory Responses1
Not AvailableCompletedTreatmentCancer Cachexia1
Not AvailableCompletedTreatmentDepression1
Not AvailableCompletedTreatmentDry Eye Syndrome (DES)1
Not AvailableCompletedTreatmentHypertriglyceridemias1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableNo Longer AvailableNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableRecruitingNot AvailableHistory of myocardial infarction / Hypertriglyceridemias1
Not AvailableTerminatedPreventionThoracic Pain1
Not AvailableTerminatedTreatmentCardiovascular Disease (CVD)1
Not AvailableUnknown StatusNot AvailableCoronary Artery Disease1
Not AvailableUnknown StatusHealth Services ResearchAttention-Deficit/Hyperactivity Disorder1
Not AvailableUnknown StatusTreatmentCoronary Artery Disease1
Not AvailableUnknown StatusTreatmentParenteral Nutrition Associated Liver Disease (PNALD)1
Not AvailableWithdrawnTreatmentPeripheral Artery Disease (PAD)1


Not Available
Not Available
Dosage forms
Capsule, liquid filledOral
Capsule, liquid filledOral1 g/1
CapsuleOral1 g/g
CapsuleOral900 mg/1
Capsule, liquid filledOral900 mg/1
Not Available
Not Available


Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available


Mass Spec (NIST)
Not Available
Not Available


Not classified


Pharmacological action
General Function
Sterol o-acyltransferase activity
Specific Function
Catalyzes the formation of fatty acid-cholesterol esters, which are less soluble in membranes than cholesterol. Plays a role in lipoprotein assembly and dietary cholesterol absorption. In addition ...
Gene Name
Uniprot ID
Uniprot Name
Sterol O-acyltransferase 1
Molecular Weight
64733.975 Da

Drug created on November 30, 2015 12:10 / Updated on May 02, 2018 00:00